Pathogenesis of Clots Following SARS-CoV-2 Vaccine Suggests Choice of Treatments
Pathologic antibodies to platelet factor 4 in patients who developed clots after the AstraZeneca vaccine indicates treatment include non-heparin anticoagulant.
Related Articles
ASM Microbe Conference: ‘Great Migration of Microbiologists’
American Society for Microbiology (ASM) CEO Stefano Bertuzzi, PhD, MPH, talks about its comprehensive scientific program, the networking opportunities at the meeting, and the unique…
A Pioneer in Coronavirus Research
In a wide-ranging interview, Susan Weiss, PhD, talks about winning the ASM Lifetime Achievement award, her work on coronaviruses, and her concerns around federal government…
3 Deaths and 17 Illnesses Tied to Listeria Outbreak From Recalled Chicken Alfredo Meals
FDA and CDC warn consumers as recalled heat-and-eat meals sold at Kroger and Walmart are tied to multiple hospitalizations, one pregnancy loss, and ongoing risks.
Bloodstream Infections in Ethiopia Reveal High Rates of Multidrug Resistance and Fungal Involvement
At ASM Microbe 2025, a cross-sectional study highlights Burkholderia cepacia dominance, widespread antibiotic resistance, and key risk factors, including invasive device use and patient demographics.
Considering the Impact of Crop Spraying and Antifungal Resistance
At the ASM Microbe conference, Mike Bromley, PhD, offers some insights on the importance of a One Health approach addressing the growing antifungal resistance to…
Outpatient C difficile Cases Reveal Diagnostic Gaps and PPI-Linked Risks
At ASM Microbe 2025, researchers underscore the role of NAAT in outpatient CDI diagnosis and raise concerns over PPI-related risk in older, healthcare-associated cases.
Evolving Challenges in C difficile Testing: Diagnostic Stewardship or Laboratory Retrogress?
Study presented at ASM Microbe 2025 questions the clinical value of adding enzyme immunoassays to PCR-based CDI diagnostics amid sensitivity concerns.
Latest Conference
Contagion® is a fully integrated news resource for practitioners and specialists to assist with the identification, diagnosis, treatment, and prevention of infectious diseases.
Dual-Targeting miRNAs Identified as Potential Therapeutics Against HCV and BVDV
Presented at ASM Microbe 2025, a bioinformatics study highlights nine human miRNAs capable of binding and potentially inhibiting both hepatitis C and bovine viral diarrhea…
FDA Approves Gilead’s Twice-Yearly Injectable Yeztugo (Lenacapavir) for HIV Prevention
Gilead’s lenacpavir, la ong-acting HIV capsid inhibitor shows 96–100% efficacy in phase 3 trials and aims to expand access worldwide through regulatory filings and support…